Eli Lilly is expanding its diabetes prospects by acquiring cell therapy developer Sigilon Therapeutics. The two companies are already partners in the development of a type 1 diabetes cell therapy currently in preclinical development.
El Lilly to Buy Sigilon, Betting the Biotech Can Overcome a Cell Therapy Limitation
